{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:05:41Z","timestamp":1785506741635,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01228-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:58:52Z","timestamp":1780300732000},"page":"541-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-9331","authenticated-orcid":false,"given":"Michael A.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karie","family":"Runcie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"1228_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1712126.","journal-title":"N Engl J Med"},{"key":"1228_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology guidelines on renal cell carcinoma: the 2025 update. Eur Urol. 2025;87:683\u201396. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020.","journal-title":"Eur Urol"},{"key":"1228_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","volume":"84","author":"MS Ernst","year":"2023","unstructured":"Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma. Eur Urol. 2023;84:109\u201316. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.001.","journal-title":"Eur Urol"},{"key":"1228_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35:1026\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.727.","journal-title":"Ann Oncol"},{"key":"1228_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2020.07.026","volume":"136","author":"R Iacovelli","year":"2020","unstructured":"Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, et al. Patients with sarcomatoid renal cell carcinoma\u2014re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020;136:195\u2013203. https:\/\/doi.org\/10.1016\/j.ejca.2020.07.026.","journal-title":"Eur J Cancer"},{"key":"1228_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","volume":"27","author":"NM Tannir","year":"2021","unstructured":"Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27:78\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2063.","journal-title":"Clin Cancer Res"},{"key":"1228_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102299","volume":"6","author":"D Stupichev","year":"2025","unstructured":"Stupichev D, Miheecheva N, Postovalova E, Lyu Y, Ramachandran A, Galkin I, et al. AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. Cell Rep Med. 2025;6:102299. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102299.","journal-title":"Cell Rep Med"},{"key":"1228_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071945","author":"A Carretero-Gonz\u00e1lez","year":"2020","unstructured":"Carretero-Gonz\u00e1lez A, Lora D, Mart\u00edn Sobrino I, S\u00e1ez Sanz I, Bourlon MT, Anido Herranz U, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12071945.","journal-title":"Cancers (Basel)"},{"key":"1228_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061673","author":"R Elaidi","year":"2020","unstructured":"Elaidi R, Phan L, Borchiellini D, Barthelemy P, Ravaud A, Oudard S, et al. Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061673.","journal-title":"Cancers (Basel)"},{"key":"1228_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","volume":"65","author":"RR McKay","year":"2014","unstructured":"McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.012.","journal-title":"Eur Urol"},{"key":"1228_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176230","author":"S Gulati","year":"2024","unstructured":"Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, et al. Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/JCI176230.","journal-title":"J Clin Investig"},{"key":"1228_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ccell.2025.03.036","volume":"43","author":"JN Cheng","year":"2025","unstructured":"Cheng JN, Jin Z, Su C, Jiang T, Zheng X, Guo J, et al. Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer Cell. 2025;43:1093-107.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.036.","journal-title":"Cancer Cell"},{"key":"1228_CR13","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1158\/1078-0432.CCR-04-2225","volume":"11","author":"J Jones","year":"2005","unstructured":"Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11:5730\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2225.","journal-title":"Clin Cancer Res"},{"key":"1228_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","volume":"23","author":"YA Vano","year":"2022","unstructured":"Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23:612\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(22)00128-0.","journal-title":"Lancet Oncol"},{"key":"1228_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3207","volume":"36","author":"SM Haake","year":"2025","unstructured":"Haake SM, Beckermann K, Barata P, Ornstein MC, Mar N, Chen YW, et al. 2591O efficacy of cabozantinib and nivolumab in cluster 1\/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker. Ann Oncol. 2025;36:S1298. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3207.","journal-title":"Ann Oncol"},{"key":"1228_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046137","volume":"104","author":"S Lin","year":"2025","unstructured":"Lin S, Yu X. Prognostic impact of liver metastases on immunotherapy in patients with advanced solid tumors: a secondary analysis of MSK-IMPACT retrospective cohort. Medicine (Baltimore). 2025;104:e46137. https:\/\/doi.org\/10.1097\/MD.0000000000046137.","journal-title":"Medicine (Baltimore)"},{"key":"1228_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/BF02574475","volume":"9","author":"A Takeda","year":"2002","unstructured":"Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol. 2002;9:610\u20136. https:\/\/doi.org\/10.1007\/BF02574475.","journal-title":"Ann Surg Oncol"},{"key":"1228_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1158\/2326-6066.CIR-23-0718","volume":"12","author":"CA Egelston","year":"2024","unstructured":"Egelston CA, Guo W, Simons DL, Ye J, Avalos C, Solomon ST, et al. Organ-specific immune setpoints underlie divergent immune profiles across metastatic sites in breast cancer. Cancer Immunol Res. 2024;12:1559\u201373. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0718.","journal-title":"Cancer Immunol Res"},{"key":"1228_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","volume":"37","author":"RJ Motzer","year":"2026","unstructured":"Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, et al. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2026;37:33\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.006.","journal-title":"Ann Oncol"},{"key":"1228_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4524","volume":"42","author":"V Gr\u00fcnwald","year":"2024","unstructured":"Gr\u00fcnwald V, Motzer RJ, Keizman D, Bedke J, Schmidinger M, Staehler MD, et al. Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): patterns of progression and subsequent therapy in the CLEAR trial. J Clin Oncol. 2024;42:4524-. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4524.","journal-title":"J Clin Oncol"},{"key":"1228_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ijc.35288","volume":"156","author":"V Gr\u00fcnwald","year":"2025","unstructured":"Gr\u00fcnwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, et al. Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial. Int J Cancer. 2025;156:1326\u201335. https:\/\/doi.org\/10.1002\/ijc.35288.","journal-title":"Int J Cancer"},{"key":"1228_CR22","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.7150\/jca.113258","volume":"16","author":"L Meng","year":"2025","unstructured":"Meng L, Psutka SP, Gheeya J, Li M, Noonavath M, Orcutt D, et al. Tyrosine kinase inhibitors outperform immune checkpoint inhibitors in bone-predominant metastatic renal cell carcinoma: a multicenter real-world analysis. J Cancer. 2025;16:4047\u201354. https:\/\/doi.org\/10.7150\/jca.113258.","journal-title":"J Cancer"},{"key":"1228_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102506","author":"A Harba","year":"2026","unstructured":"Harba A, Moinard-Butot F, Auclin E, Barth\u00e9l\u00e9my P, Noel J, Dumont C, et al. Real-world outcomes of first-line immune-based combination therapies in bone-metastatic clear cell renal cell carcinoma. Clin Genitourin Cancer. 2026. https:\/\/doi.org\/10.1016\/j.clgc.2026.102506.","journal-title":"Clin Genitourin Cancer"},{"key":"1228_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-33198-x","volume":"16","author":"S Toyoda","year":"2026","unstructured":"Toyoda S, Inoki L, Hashimoto M, Fukuokaya W, Mori K, Nishimura S, et al. Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma. Sci Rep. 2026;16:3303. https:\/\/doi.org\/10.1038\/s41598-025-33198-x.","journal-title":"Sci Rep"},{"key":"1228_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.21873\/anticanres.17451","volume":"45","author":"G Yamamichi","year":"2025","unstructured":"Yamamichi G, Kato T, Yoshimura A, Tani M, Horibe Y, Liu Y, et al. Efficacy of second-line nivolumab versus tyrosine kinase inhibitors for renal cell carcinoma with bone metastases. Anticancer Res. 2025;45:639\u201350. https:\/\/doi.org\/10.21873\/anticanres.17451.","journal-title":"Anticancer Res"},{"key":"1228_CR26","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298\u2013308. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0264.","journal-title":"Mol Cancer Ther"},{"key":"1228_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41585-018-0034-9","volume":"15","author":"V Gr\u00fcnwald","year":"2018","unstructured":"Gr\u00fcnwald V, Eberhardt B, Bex A, Fl\u00f6rcken A, Gauler T, Derlin T, et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol. 2018;15:511\u201321. https:\/\/doi.org\/10.1038\/s41585-018-0034-9.","journal-title":"Nat Rev Urol"},{"key":"1228_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","volume":"42","author":"EF Gillespie","year":"2024","unstructured":"Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial. J Clin Oncol. 2024;42:38\u201346. https:\/\/doi.org\/10.1200\/JCO.23.00753.","journal-title":"J Clin Oncol"},{"key":"1228_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.prro.2024.04.018","volume":"14","author":"S Alcorn","year":"2024","unstructured":"Alcorn S, Cort\u00e9s \u00c1A, Bradfield L, Brennan M, Dennis K, Diaz DA, et al. External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2024;14:377\u201397. https:\/\/doi.org\/10.1016\/j.prro.2024.04.018.","journal-title":"Pract Radiat Oncol"},{"key":"1228_CR30","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.ejso.2016.03.036","volume":"42","author":"MN Kirkinis","year":"2016","unstructured":"Kirkinis MN, Lyne CJ, Wilson MD, Choong PF. Metastatic bone disease: a review of survival, prognostic factors and outcomes following surgical treatment of the appendicular skeleton. Eur J Surg Oncol. 2016;42:1787\u201397. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.036.","journal-title":"Eur J Surg Oncol"},{"key":"1228_CR31","doi-asserted-by":"publisher","first-page":"68890","DOI":"10.18632\/oncotarget.20323","volume":"8","author":"K Omae","year":"2017","unstructured":"Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, et al. Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8:68890\u20138. https:\/\/doi.org\/10.18632\/oncotarget.20323.","journal-title":"Oncotarget"},{"key":"1228_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.33696\/cancerimmunol.5.072","volume":"5","author":"M Stout","year":"2023","unstructured":"Stout M, Thaper A, Xu V, Singer EA, Saraiya B. Early integration of palliative care for patients receiving systemic immunotherapy for renal cell carcinoma. J Cancer Immunol. 2023;5:5\u201312. https:\/\/doi.org\/10.33696\/cancerimmunol.5.072.","journal-title":"J Cancer Immunol"},{"key":"1228_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","volume":"211","author":"C Gr\u00fcllich","year":"2018","unstructured":"Gr\u00fcllich C. Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res. 2018;211:67\u201375. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_5.","journal-title":"Recent Results Cancer Res"},{"key":"1228_CR34","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01228-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:15Z","timestamp":1785503715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01228-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01228-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael A. Liu, Kyle Miyazaki, Karie Runcie, and Hanna Cash declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Lingbin Meng has served on advisory boards for Astellas Pharma and Dendreon, and has provided consulting services to Clinical Care Solutions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael A. Liu: conceptualization, writing\u2014original draft, and writing\u2014reviewing and editing. Kyle Miyazaki: writing\u2014review and editing. Karie Runcie: writing\u2014review and editing. Hanna Cash: writing\u2014review and editing. Lingbin Meng: writing\u2014review and editing.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}